-
A First-in-Human Phase 1a/1b Trial to Assess the Safety Tolerability and Preliminary Efficacy of LY4170156 an Antibody-Drug Conjugate Targeting Folate Receptor a Expressing Tumor Cells in Participants with Selected Advanced Solid Tumors
This study will test a new drug called LY4170156, an antibody drug conjugate (ADC) to see how it works in the body, and if it ...
-
A Phase 1 Study of MOMA-313 Given as Monotherapy or in Combination With a PARP Inhibitor in Participants With Advanced or Metastatic Solid Tumors
This is a study testing MOMA-313, a drug that blocks a protein called DNA polymerase theta (Pol?) for prostate cancer with a genetic feature called ...
-
Targeting CD38 with Daratumumab in Primary Antiphospholipid Syndrome: A Phase 1b Dose Escalation Safety Trial
The purpose of this research study is to assess the safety of daratumumab (Darzalex®) and whether it may reduce levels of antiphospholipid antibodies, a blood ... -
A Phase 1b Study of JNJ-78278343 a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2) in Combination with either JNJ-63723283 (cetrelimab) Taxane Chemotherapy or Androgen Receptor Pathway Inhibitors for Metastatic Castration- Resistant Prostate Cancer
This study will test the early effects of the immunotherapy drug JNJ-78278343, a bispecific antibody targeting KLK2 and CD3, combined with taxane chemotherapy or androgen ...
-
Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects with Advanced or Metastatic Solid Tumors
This is study is testing a new medicine called AFNT-211 for patients with advanced or metastatic (cancer that has spread) that has specific genetic markers ...
-
An Open-label Phase 1 Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of NT-112 in Human Leukocyte Antigen-C*08:02-Positive Adult Subjects with Unresectable Advanced and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation
This study is testing a NT-112, a type of cellular therapy, in patients with advanced cancer, such as lung, pancreatic, or colorectal cancer, who have ...
-
Randomized Double-Blind Placebo-controlled Safety Study of Glial Cell Line-Derived Neurotrophic Factor Gene Transfer (AAV2-GDNF) in Multiple System Atrophy
In this clinical trial, we are testing a drug called glial cell line-derived neurotrophic factor (GDNF) gene transfer to see if it helps people with ... -
A Phase 1a/1b First-in-human Multicenter Study to Assess the Efficacy and Safety of RGT-61159 for Treatment of Patients with Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
This study will test the potential tumor-fighting effects of a daily medication called RGT-61159 for patients with advanced ACC or CRC, two types of cancer ...
-
A PHASE IB STUDY TO ASSESS SAFETY OF CONCURRENT AZELIRAGON WITH CRANIOSPINAL IRRADIATION IN PATIENTS WITH LEPTOMENGINAL METASTASIS FROM SOLID TUMOR MALIGNANCIES OR HIGH-GRADE GLIOMAS
This study is a Phase 1b clinical trial at a single hospital to test the tolerability and safety of combining the drug Azeliragon with craniospinal ...
-
A Phase 1 Study of NKX019 a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy in Subjects with Lupus Nephritis
The purpose of this study is to investigate NKX019, which is made from one type of white blood cell called a natural killer (NK) cell ...